Australia Age-Related Macular Degeneration Market Size, Share, Forecast to 2026-2034

Market Overview

The Australia age-related macular degeneration (AMD) market reached USD 209.12 Million in 2025 and is projected to attain USD 239.47 Million by 2034. It is expected to grow steadily at a CAGR of 1.52% during the forecast period 2026-2034. This growth is propelled by Australia's aging population, enhanced government reimbursement policies, and advancements like artificial intelligence improving early diagnosis and disease monitoring. These combined factors are expanding the market opportunities substantially. For detailed insights, visit the Australia Age-Related Macular Degeneration Market

How AI is Reshaping the Future of Australia Age-Related Macular Degeneration Market:

Advanced deep learning algorithms now analyze optical coherence tomography scans and fundus photographs with accuracy comparable or superior to human specialists, improving diagnostic precision.

AI models are being developed to predict AMD disease progression and optimize treatment intervals for anti-VEGF injections, enhancing personalized patient care.

Automated AI screening programs enable early AMD detection, facilitating intervention before significant vision loss occurs.

AI-driven telemedicine platforms allow remote screening and monitoring, critical for Australia's rural and remote populations facing geographic healthcare access challenges.

A qualitative study at UNSW Sydney showed growing clinical acceptance of AI diagnostics in AMD, with stakeholders anticipating a fee-for-service model for remote patient monitoring.

Successful AI integration requires validated algorithms for diverse populations, ongoing clinical oversight, and robust data governance to ensure ethical use and patient privacy.

Grab a sample PDF of this report: https://www.imarcgroup.com/australia-age-related-macular-degeneration-market/requestsample

Market Growth Factors

The rapidly aging Australian population is a primary growth driver for the AMD market. AMD remains the leading cause of blindness among Australians over 50, affecting around 1.25 million people nationally, with projections rising to 1.7 million as the population ages. The Australian Bureau of Statistics forecasts nearly one in four Australians will be aged 65 or older by 2066, significantly enlarging the at-risk demographic. This demographic expansion increases demand for diagnostic services, anti-VEGF therapies, and specialist ophthalmological care. Healthcare systems are expanding screening programs and specialist capacity to accommodate this growth, driving steady demand and healthcare expenditure for AMD treatments.

Government initiatives play a crucial role in improving accessibility and affordability of AMD treatments. The 2022 launch of the National Strategic Action Plan for Macular Disease coordinates efforts across government levels to enhance service delivery and funding. The Pharmaceutical Benefits Scheme subsidizes key anti-VEGF drugs including Lucentis, Eylea, Beovu, and Vabysmo, significantly reducing patient costs and enabling better access. Collaboration between federal and state health departments aims to expand public hospital eye injection clinic capacity, ensuring sufficient treatment availability. These efforts reflect strong political will to address AMD as a health priority and support market growth through improved infrastructure and reimbursement policies.

Artificial intelligence is fundamentally transforming Australia's AMD diagnosis and management landscape. AI algorithms provide diagnostic accuracy on par with expert retinal specialists and enable disease progression prediction, treatment optimization, and early detection via automated screening. These advances are particularly impactful in overcoming geographic disparities by facilitating remote patient monitoring and reducing specialist visit frequency. Telemedicine platforms equipped with AI diagnostics allow preliminary screening in primary care, with specialist referrals for confirmed cases. Such AI-driven innovations improve treatment personalization, health resource utilization, and accessibility, positioning AI as a key growth catalyst in the AMD market.

Market Segmentation

Analysis by Product:

Eylea

Lucentis

Beovu

Others

Analysis by Disease Type:

Wet Age-related Macular Degeneration

Dry Age-related Macular Degeneration

Analysis by Region:

Australia Capital Territory & New South Wales

Victoria & Tasmania

Queensland

Northern Territory & Southern Australia

Western Australia

Key Players

Not provided in source.

Recent Development & News

January 2025: The Australian government expanded its National Strategic Action Plan for Macular Disease, focusing on increasing diagnostic services in underserved regional and rural areas. This initiative enhances early detection and treatment accessibility, addressing geographic disparities and supporting the growing patient population.

June 2025: BenoBio initiated a Phase I clinical trial in Australia for BBRP11001 (BBC1501), a novel small-molecule inhibitor targeting neovascular AMD patients unresponsive to conventional anti-VEGF therapies. This highlights pharmaceutical innovation addressing unmet clinical needs within the market.

September 2025: Researchers from UNSW Sydney reported increased acceptance of AI-driven diagnostic tools among clinicians, healthcare leaders, and patients. Planned implementation of fee-for-service remote AMD identification models signals growing integration of AI, improving disease management and healthcare efficiency.

Note: If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

Ask an analyst for your customized sample: https://www.imarcgroup.com/request?type=report&id=44015&flag=C

About Us

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group,

134 N 4th St. Brooklyn, NY 11249, USA,

Email: sales@imarcgroup.com,

Tel No: (D) +91 120 433 0800,

United States: +1-201-971-6302